Cytokines in metastatic renal cell carcinoma: Is it useful to switch to interleukin-2 or interferon after failure of a first treatment?

Journal of Clinical Oncology

Volumn 17, Issue 7, 1999, Pages 2039-2043

  Escudier, Bernard ^a   Chevreau, Christine ^a   Lasset, Christine ^a   Douillard, Jean Yves ^a   Ravaud, Alain ^a   Fabbro, Michel ^a   Caty, Armelle ^a   Rossi, Jean Francois ^a   Viens, Patrice ^a   Bergerat, Jean Pierre ^a   Savary, Jacqueline ^a   Négrier, Sylvie ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; INTERLEUKIN 2;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; SKIN TOXICITY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT FAILURE;

EID: 0033056820     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.7.2039     Document Type: Article

References (17)

1. De Kernion JB, Ramming KP, Smith RB: The natural history of metastatic renal cell carcinoma: A computer analysis. J Urol 120:148-152, 1993
2. Elson PJ, Witte RS, Trump DL: Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48:7310-7313, 1988
3. Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N Engl J Med 335:865-875, 1996
4. Rosenberg SA, Lotze MT, Muul LM, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485-1492, 1985
5. Rosenberg SA, Lotze MT, Muul LM, et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889-897, 1987
6. West WH, Tauer KW, Yanelli JR, et al: Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898-905, 1987
7. Négrier S, Philip T, Stoter G, et al: Interleukin 2 with or without LAK cells in metastatic renal cell carcinoma: A report of a European multicenter study. Eur J Cancer Clin Oncol 25:21-28, 1990
8. Dillman RO, Oldham RK, Tauer KW, et al: Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: A National Biotherapy Study Group trial. J Clin Oncol 9:1233-1240, 1991
9. Atkins MB, Sparano J, Fisher RI, et al: Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 11:661-670, 1993
10. Négrier S, Escudier B, Lasset C, et al: Interleukin 2, interferon or both in 425 patients with metastatic renal cell carcinoma: Results of a multicentre randomized trial. N Engl J Med 338:1272-1278, 1998
11. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
12. Thiesse P, Ollivier L, Di Stefano-Louineau D, et al: Response rate accuracy in oncological trials: Reasons for interobserver variability. J Clin Oncol 15:3507-3514, 1997
13. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
14. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1996
15. Lissoni P, Barni S, Ardizzoia A, et al. Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha. Eur J Cancer 28:192-196, 1992
16. Fossa SD, Kramar A, Droz JP: Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 30A:1310-1314, 1994
17. Palmer PA, Vinke J, Philip T, et al: Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 3:475-480, 1992